Osimertinib
Osimertinib
Osimertinib (pronounced oh-si-mer-ti-nib) is a medication used in the treatment of non-small cell lung cancer (NSCLC) that is locally advanced or metastatic. It is specifically used for NSCLC that is positive for the epidermal growth factor receptor (EGFR) mutation.
Etymology
The name "Osimertinib" is derived from the components of the drug. "Os" is derived from the Latin word for bone, referring to the drug's target in the bone marrow. "Mert" is derived from the word "merit", referring to the drug's effectiveness. "Nib" is a common suffix used in the names of tyrosine kinase inhibitors, which is the class of drugs to which Osimertinib belongs.
Usage
Osimertinib is used as a first-line treatment for patients with metastatic NSCLC whose tumors have specific EGFR mutations. It is also used for patients whose disease has progressed on or after EGFR TKI therapy.
Mechanism of Action
Osimertinib works by inhibiting the activity of the EGFR, a protein that is overactive in many types of cancer cells. By blocking this protein, Osimertinib can help to slow the growth and spread of cancer cells.
Related Terms
- Non-small cell lung cancer: This is the most common type of lung cancer, and it is the condition for which Osimertinib is most commonly prescribed.
- Epidermal growth factor receptor: This is the protein that Osimertinib targets in order to slow the growth and spread of cancer cells.
- Tyrosine kinase inhibitors: This is the class of drugs to which Osimertinib belongs. These drugs work by blocking the activity of certain proteins that can contribute to the growth and spread of cancer cells.
External links
- Medical encyclopedia article on Osimertinib
- Wikipedia's article - Osimertinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski